SlideShare ist ein Scribd-Unternehmen logo
1 von 31
Downloaden Sie, um offline zu lesen
Are nanostructured lipid carriers (NLCs)
better than solid lipid nanoparticles(SLNs):
Development, characterizations and
comparative evaluations of clotrimazole-
loaded SLNs and NLCs?
Presented by
Devendra singh
Contents
Introduction.
Material and methods.
Characterization.
Result and discussion.
Conclusion.
Introduction
 From the recent past, biocompatible lipids have been attracting the attention of the formulation
scientists as carriers for the delivery of poorly soluble drugs (Pouton, 2006).
 Among biocompatible lipids, lipid nanoparticle formulations with solid matrix have gained huge
popularity.
 Generally, there are two types of lipid nanoparticles with solid matrix, solid lipid nanoparticles (SLNs)
and nanostructured lipid carriers (NLCs) (Das and Chaudhury, 2011).
 Theses nanoparticles can be widely applied to deliver drugs/actives through oral, parenteral and
topical routes (Almeida and Souto, 2007; Das and Souto, 2007.
 However, the current focus of the SLNs and NLCs research is more inclined towards topical
(especially dermal) application both in pharmaceutical and cosmetic purposes (Pardeike et al., 2009).
SLNs are beneficial in many aspects such as:
 possess negligible toxicity.
 lipophilic compounds can be easily encapsulated.
 bioavailability of highly lipophilic molecules can be increased via lymphatic uptake.
 degradation of chemical/moisture/light/oxidation sensitive molecules can be
prevented by their incorporation in the nanoparticle matrix.
 sustained drug release from the nanoparticle matrix is possible due to solid nature of
the matrix leading to prolonged drug release.
 penetration through skin or mucus barrier is possible due to nano size.
drawbacks of SLNs
 polymorphic transitions of the lipid may occur with time due to the crystalline
structure of solid lipid (Müller et al., 2002).
 Lipid crystallizes in high-energetic lipid modifications, α and β immediately after
preparation of SLNs.
 In general, drug molecules stay in between the fatty acid chains or as amorphous
clusters in crystal imperfections within SLN matrix. But, when lipid transform to low-
energetic form, it form a perfect crystalline lattice that allows very small space for the
drug molecules. Therefore, expulsion of encapsulated drug molecules may be
observed during storage which leads to limited drug-loading capacity of SLNs.
are nanostructured lipid carrier are better then solid lipid nanoparticles
NLCs as alternate drug carrier systems over SLNs
 In the process of further improvement and reduction of these drawbacks of
SLNs, NLCs have been evolved as alternative drug carrier systems.
 NLC matrix is composed of mixture of spatially different lipid molecules,
normally mixture of solid and liquid lipid, which makes more imperfection in
the matrix to accommodate more drug molecules than SLN.
 It is expected that the drug-loading capacity will be enhanced, drug expulsion
during storage will be minimized due to the imperfect crystal lattice and drug
release profile can be easily modulated by varying the lipid matrix
composition (Müller et al., 2002a; Radtke et al., 2005).
Formulation technique:
Emulsification ultra sonication technique:
Melted lipid or lipid mixture
o/w Nano emulsion
Immediately placed in double walled
plastic box filled with ice to cool it
down
The liquid nano-droplet transformed
into solid nanoparticles dispersions
Coarse o/w emulsion
drug
hot aqueous surfactant solution
homogenize at 14000- 15000rpm
Sonication at 75 c
In case of SLNs solid lipid was
weighed and heated 75 c
In case of NLCs solid and liquid
lipid heated 75 c
Characterization
Particle size, polydispersity index and zeta potential measurement:
 For particle size and polydispersity index measurements, the diluted nanoparticle
dispersion was poured into the disposable sizing cuvette which was then placed in
the cuvette holder of the instrument and analyzed using the zetasizer software
(DTS v 6.12, Malvern Instruments, UK).
 For zeta potential measurement, disposable folded capillary cuvette was used. Air
bubbles, if any, were removed from the capillary before measurement. All
measurements were performed in triplicate.
Drug loading and encapsulation efficiency
measurement:
Drug loading and encapsulation efficiency were determined by measuring the amount of
encapsulated drug within the nanoparticles (Das et al., 2011).
Unencapsulated insoluble drug (if any) were first filtered out through 3lm nitrocellulose
membrane filter. Then, methanol (9.5 mL) was added in the filtered formulation(0.5 mL)
and mixed well with the help of a cyclomixer. then centrifuged for 15 min at 5000 rpm and
supernatant was collected. The drug concentration in the supernatant was measured by
HPLC
Drug encapsulation efficiency (EE) and drug loading (L) were calculated using the
following equations:
EE(%)= actual amount of drug in the filtered formulation-soluble unencapsulated drug x100
amount of drug added during formulation
L(%) = actual amount of encapsulated drug x100
amount of lipid used to prepare the formulation
Scanning electron microscopy study
 Some researchers have used SEM for the morphology of SLNs (Varshosaz et al., 2010), the
nanoparticles may not maintain their integrity and solid state during SEM analysis due to
the increase in energy during measurment. Therefore, cryogenic field emission scanning
electron microscopy was used to examine shape, size and surface morphology of the
SLNs/NLCs.
 few drops of the nanoparticle dispersion were placed on a copper stub and frozen in
nitrogen slush at -196 C. The frozen sample was then stored in liquid nitrogen and
transferred into the cryo preparation chamber attachedto a FESEM where the frozen
sample was freeze-fractured, sublimed for 30 s at -95 C and sputtercoated with platinum
for 120 s. Then the coated sample was placed onto the specimen stage of the FESEM
at140 C and analyzed at an excitation voltage of 5 kV.
Differential scanning calorimetry analysis
 Firstly SNLs and NLCs samples are lyophilized, filled and blank NLCs and SLNs were
subjected to DSC.
 samples(4–5 mg) were kept in the standard aluminum pans and sealed. Then the pans
were placed under isothermal condition at 25 C for 10 min. DSC analysis was
performed at 10 C/min from 25 to 290C under a inert environment. An empty sealed
pan was used as reference. The thermograms of the samples were recorded
Drug release study
The dialysis bag method was followed for the drug release study The day before the drug
release experiment, dialysis tube (10 kDa molecular cut off) was treated closely following the
protocol (Sigma) and soaked in the release media overnight. Phosphate buffer at pH 7.4
containing 2% Tween 80 was used as drug release media.
Accurately measured 1 mL formulation was placed in the dialysis tube and both end of the tube
was tightly tied to prevent any leakage. The tube containing formulation was then kept in an
amber colored glass bottle containing 10 mL release media. The bottle was kept on a horizontal
rotary shaker rotating at 100 rpm. Samples (5 mL release media) were withdrawn from the
bottle at the predetermined time intervals and replaced by 5 mL fresh release media. The
samples were then analyzed by HPLC to determine the amount of drug released from the
formulation at different time points.
Results and Discussion
Particle size
 Particle size measurement was required to confirm the production of the particles in nano-
range.
 particle size was significantly influenced by most of the formulation and process variables.
 Among the different lipid tested, SLNs prepared using Compritol 888ATO were smallest
and SLNs prepared using Dynasan 118 were biggest.
 However, no relationship between chemical structure of the lipids and particle size was
observed. This might be because of the complex structure of these lipids.
are nanostructured lipid carrier are better then solid lipid nanoparticles
Effect of surfactant on particle size
 Among the 4 non-ionic surfactant tested, SLNs prepared using
Chremophore EL demonstrated lowest size, whereas SLNs prepared
using PluronicF68 demonstrated largest size (fig.b)
 Hydrophilic-lipophilic balance (HLB) value of 12–16 is considered
to be ideal for the production of stable o/w emulsion.
 In contrast, HLB value of Pluronic F68 is very high (>24). This
might be the main reason of bigger particle size when PluronicF68
was used.
are nanostructured lipid carrier are better then solid lipid nanoparticles
Effect of sonication time on particle size.
Particle size dramatically decreased with increasing sonication time
However, the size reduction was not huge above 10 min sonication
time. (Fig. 1C)
Particle size dramatically decreased with increasing
surfactant concentration (Fig. 1D).
Polydispersity index
 Polydispersity index (PI) indicates the width of the particle size
distribution, which ranges from 0 to 1.
 Theoretically, monodisperse populations indicates PI = 0. However, PI < 0.2 is
considered as narrow size distribution.
 Among the lipids, Compritol 888ATO produced SLNs with lowest PI and
Geleol™ produced SLNs with highest PI (Fig. 1A).
 Among the surfactants Chremophore EL produced SLNs with lowest PI and
Pluronic F68 produced SLNs with highest PI (Fig. 1B).
 PI decreased with increasing sonication time (up to 15 min) and surfactant
concentration. PI was very high at 1–5 min sonication time and 0.5–1% surfactant
concentration.
Zeta potential
 ZP refers to the surface charge of the particles. ZP ( ) indicates the degree of
repulsion between close and similarly charged particles in the dispersion.
 This repulsion force prevents aggregation of the particles. Therefore, ZP is a
useful parameter to predict the physical stability of the SLN/NLC dispersions
(Das and Chaudhury, 2011; Freitas and Müller, 1998).
 The results indicate that ZP values were less than -20 mV for all prepared SLNs
and NLCs, except SLNs prepared at 1% lipid concentration.
 ZP of the SLNs prepared with different lipids decreased as follows: Precirol ATO5
> Compritol 888ATO > Suppocire NC > Geleol™ > Dynasan 114 > Imwitor 900
K > Dynasan118 (Fig. 1A)
 There was no specific correlation between ZP and solid to liquid lipid ratio in
NLCs (Fig. 2A).
Drug encapsulation efficiency
 Drug encapsulation efficiency (EE) was highest and lowest when SLNs were prepared with
Compritol 888ATO (>87%) and Dynasan 118 (<76%) as lipid, respectively (Fig. 1A).
 SLNs prepared with Chromophore EL as surfactant showed highest EE (>87%) (Fig. 1B).
However, EE was > 79% when SLNs prepared with other surfactants too.
 The results showed that EE of SLNs was not dependant on sonication time (Fig. 1C).
 EE of SLNs significantly increased with increasing surfactant concentration.
 However, insignificant increase in EE was noticed above 2% surfactant concentration. (Fig.
1D).
Scanning electron microscopy
 The images indicate that both SLNs and NLCs were spherical with size between 50 and
150 nm. Although it was not common, some particle agglomerates were observed (Fig.
3C).
 The particle aggregations might be due to sticky nature of the lipid.
 Surface morphology of both SLNs and NLCs were smooth and there is no visible
difference between them (Fig. 3B–D).
 The crystalline structures of clotrimazole were absent in the SEM images of SLNs and
NLCs, which suggests absence of unencapsulated undissolved drug crystals in the
dispersions.
Fig. 3. SEM images of clotrimazole (A), solid lipid nanoparticles (B and C) and nanostructured lipid carriers (D)
Drug release
 Cumulative drug release from the nanoparticle dispersions were plotted against
time (Fig.6).
 SLNs and NLCs prepared at 4% drug to lipid ratio showed sustained and
prolonged drug release. However, drug release rate of NLCs 4% was significantly
faster than SLN-4% . (Fig. 6A)
 Both SLNs and NLCs prepared at 8% drug to lipid ratio (i.e., SLN-8% and NLC-
8%) showed significantly slower drug release rate than their counterparts with 4%
drug to lipid ratio.
 There was no significant difference in drug release profile or rate between SLN-8%
and NLC-8% .
 There was also no significant difference in drug release profile of NLCs after 3
months storage in compare to fresh NLCs, while significant change drug release
rate was observed in case of SLNs.
Drug release plots. Comparison of drug release from SLNs and NLCs at 4% (SLN-4% and NLC-4%) and 8% (SLN-8% and NLC-8%) drug to
lipid ratio (A). Effect of release media volume (10 mL versus 20 mL) on drug release from SLN-8% (B). Effect of dilution of SLNs-4% on
drug release (C). Comparison of drug release from fresh and 3 months old SLN-4% and NLC-4% stored at 2–8C (D). Data represent mean
SD (n= 3).
Drug release contd..
 lower drug release at 8% drug to lipid ratio than 4% drug to lipid ratio might be due to
absence of proper sink condition during drug release study as drug amount was doubled but
volume of release media was same (10 mL).
 Therefore, another drug release experiment was performed on SLNs prepared with 8%
drug to lipid ratio using 20 mL release media. The result indicates slightly faster drug
release when 20 mL release media was used than 10 mL release media. (Fig. 6B)
 In another experiment, effect of dilution of formulation on drug release was investigated.
The experiment was performed as formulation is diluted after oral ingestion (in gastric
fluid) or intravenous injection (in blood), whereas almost no dilution occur during topical
application on skin. In this experiment, SLN dispersion was diuted 5 times with ultrapure
water and then release study was performed in 10 mL release media (Fig. 6C).
Conclusion
 The study suggests the importance of controlling the critical formulation and
process parameters during formulation as they greatly influenced the final
product, such as particle size, polydispersity index, zeta potential, drug
encapsulation efficiency.
 Chemical characterizations (DSC) demonstrated slight difference in crystal
structure between SLNs and NLCs, although crystalline peak(s) of clotrimazole
disappeared in both SLNs and NLCs.
 Sustained drug release was observed from SLNs and NLCs. NLCs exhibit the
same release pattern after 3 month as fresh, while significant change was observed
in case of SLNs
 In the comparative study, NLCs exhibited faster drug release than SLNs at the low
drug-loading.
 Both tested SLNs and NLCs were stable at 2–8 C even at high drug-loading and
also stable at 25 c at low drug loading. therefore, NLCs have an edge over SLNs.
 Although both SLN and NLCs can be used as effective carrier of lipophilic drugs
depending on desired drug release profile, NLCs might be better option than
SLNs. Nevertheless different stabilizing route need to be evaluated in near future.
Reference
 Das S, Ng Wai K, Tan R. “Are nanostructured lipid carriers (NLCs) better than solid lipid
nanoparticles(SLNs): Development, characterizations and comparative evaluations of
clotrimazole-loaded SLNs and NLCs?” Euro. Jur. Of ph sci. june 1, 2012.
Thank you

Weitere ähnliche Inhalte

Was ist angesagt? (20)

Nanoparticles and liposomes ppt
Nanoparticles and liposomes pptNanoparticles and liposomes ppt
Nanoparticles and liposomes ppt
 
Nanosuspension
NanosuspensionNanosuspension
Nanosuspension
 
Preparation methods of polymeric nanoparticles
Preparation methods of polymeric nanoparticlesPreparation methods of polymeric nanoparticles
Preparation methods of polymeric nanoparticles
 
Polymeric nano particles
Polymeric nano particles Polymeric nano particles
Polymeric nano particles
 
Nanoparticle for drug delivery system
Nanoparticle for drug delivery systemNanoparticle for drug delivery system
Nanoparticle for drug delivery system
 
Transferosomes
TransferosomesTransferosomes
Transferosomes
 
Nanoparticle
NanoparticleNanoparticle
Nanoparticle
 
Nanoparticles
NanoparticlesNanoparticles
Nanoparticles
 
Solid Lipid Nanoparticle
Solid Lipid NanoparticleSolid Lipid Nanoparticle
Solid Lipid Nanoparticle
 
PARENTERAL CONTROLLED DRUG DELIVERY SYSTEMS,
PARENTERAL CONTROLLED DRUG DELIVERY SYSTEMS,PARENTERAL CONTROLLED DRUG DELIVERY SYSTEMS,
PARENTERAL CONTROLLED DRUG DELIVERY SYSTEMS,
 
Niosomes
NiosomesNiosomes
Niosomes
 
Niosomes
NiosomesNiosomes
Niosomes
 
Liposome ppt
Liposome pptLiposome ppt
Liposome ppt
 
Liposome preparation and evaluation
Liposome preparation and evaluationLiposome preparation and evaluation
Liposome preparation and evaluation
 
Ethosomes
EthosomesEthosomes
Ethosomes
 
Solid lipid nanoparticles ppt
Solid lipid nanoparticles pptSolid lipid nanoparticles ppt
Solid lipid nanoparticles ppt
 
Pharmacosomes
PharmacosomesPharmacosomes
Pharmacosomes
 
Solid lipid nanopaticle as promising drug
Solid lipid nanopaticle  as promising drugSolid lipid nanopaticle  as promising drug
Solid lipid nanopaticle as promising drug
 
Transferosomes
Transferosomes Transferosomes
Transferosomes
 
Nanoemulsions
NanoemulsionsNanoemulsions
Nanoemulsions
 

Andere mochten auch

Solid lipid nanoparticles
Solid lipid nanoparticlesSolid lipid nanoparticles
Solid lipid nanoparticlesAnay Kacharia
 
Solid lipid nanoparticle
Solid lipid nanoparticleSolid lipid nanoparticle
Solid lipid nanoparticleSagar Savale
 
Nanostructure lipid carrier rahul dalvi
Nanostructure lipid carrier rahul dalviNanostructure lipid carrier rahul dalvi
Nanostructure lipid carrier rahul dalviRahul Dalvi
 
Preparation of Nanoparticles
Preparation of NanoparticlesPreparation of Nanoparticles
Preparation of Nanoparticleshephz
 
Nanoparticles
NanoparticlesNanoparticles
NanoparticlesGaurav Kr
 
Nanoparticles powerpoint
Nanoparticles powerpointNanoparticles powerpoint
Nanoparticles powerpointeyfanatic
 
Solid Lipid Nano particles of Alendronate Sodium
 Solid Lipid Nano particles of Alendronate Sodium Solid Lipid Nano particles of Alendronate Sodium
Solid Lipid Nano particles of Alendronate SodiumRohit Suman
 
Faktor-Faktor yang Berpengaruh Terhadap Proses Pelepasan, Pelarutan dan Abso...
Faktor-Faktor yang Berpengaruh Terhadap  Proses Pelepasan, Pelarutan dan Abso...Faktor-Faktor yang Berpengaruh Terhadap  Proses Pelepasan, Pelarutan dan Abso...
Faktor-Faktor yang Berpengaruh Terhadap Proses Pelepasan, Pelarutan dan Abso...Surya Amal
 
1 2 sistem zat padat farmasi fisik
1 2 sistem zat padat farmasi fisik1 2 sistem zat padat farmasi fisik
1 2 sistem zat padat farmasi fisikapriantoaris7
 
Formation of crystalline nanosized titania in reverse micelles at room
Formation of crystalline nanosized titania in reverse micelles at roomFormation of crystalline nanosized titania in reverse micelles at room
Formation of crystalline nanosized titania in reverse micelles at roomWeeraman Buraso
 
NRL-SEAP Presentation
NRL-SEAP PresentationNRL-SEAP Presentation
NRL-SEAP Presentationbarton814
 
Polymeric nanoparticles for encapsulation and controlled release of bioactive...
Polymeric nanoparticles for encapsulation and controlled release of bioactive...Polymeric nanoparticles for encapsulation and controlled release of bioactive...
Polymeric nanoparticles for encapsulation and controlled release of bioactive...Tomsk Polytechnic University
 
Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...
Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...
Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...Tomsk Polytechnic University
 

Andere mochten auch (20)

Solid lipid nanoparticles
Solid lipid nanoparticlesSolid lipid nanoparticles
Solid lipid nanoparticles
 
Solid lipid nanoparticle
Solid lipid nanoparticleSolid lipid nanoparticle
Solid lipid nanoparticle
 
Nanostructure lipid carrier rahul dalvi
Nanostructure lipid carrier rahul dalviNanostructure lipid carrier rahul dalvi
Nanostructure lipid carrier rahul dalvi
 
NLC
NLCNLC
NLC
 
Solid lipid n ps
Solid lipid n psSolid lipid n ps
Solid lipid n ps
 
Preparation of Nanoparticles
Preparation of NanoparticlesPreparation of Nanoparticles
Preparation of Nanoparticles
 
Nanoparticles
NanoparticlesNanoparticles
Nanoparticles
 
Nanoparticle
NanoparticleNanoparticle
Nanoparticle
 
Presentation On Nanoparticles
Presentation On NanoparticlesPresentation On Nanoparticles
Presentation On Nanoparticles
 
Nanoparticles powerpoint
Nanoparticles powerpointNanoparticles powerpoint
Nanoparticles powerpoint
 
aniruddh training report
aniruddh training reportaniruddh training report
aniruddh training report
 
Solid Lipid Nano particles of Alendronate Sodium
 Solid Lipid Nano particles of Alendronate Sodium Solid Lipid Nano particles of Alendronate Sodium
Solid Lipid Nano particles of Alendronate Sodium
 
Faktor-Faktor yang Berpengaruh Terhadap Proses Pelepasan, Pelarutan dan Abso...
Faktor-Faktor yang Berpengaruh Terhadap  Proses Pelepasan, Pelarutan dan Abso...Faktor-Faktor yang Berpengaruh Terhadap  Proses Pelepasan, Pelarutan dan Abso...
Faktor-Faktor yang Berpengaruh Terhadap Proses Pelepasan, Pelarutan dan Abso...
 
1 2 sistem zat padat farmasi fisik
1 2 sistem zat padat farmasi fisik1 2 sistem zat padat farmasi fisik
1 2 sistem zat padat farmasi fisik
 
Formation of crystalline nanosized titania in reverse micelles at room
Formation of crystalline nanosized titania in reverse micelles at roomFormation of crystalline nanosized titania in reverse micelles at room
Formation of crystalline nanosized titania in reverse micelles at room
 
NRL-SEAP Presentation
NRL-SEAP PresentationNRL-SEAP Presentation
NRL-SEAP Presentation
 
Research
ResearchResearch
Research
 
Polymeric nanoparticles for encapsulation and controlled release of bioactive...
Polymeric nanoparticles for encapsulation and controlled release of bioactive...Polymeric nanoparticles for encapsulation and controlled release of bioactive...
Polymeric nanoparticles for encapsulation and controlled release of bioactive...
 
Temozolomide And Doxorubicin Delivery
Temozolomide And Doxorubicin DeliveryTemozolomide And Doxorubicin Delivery
Temozolomide And Doxorubicin Delivery
 
Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...
Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...
Chitosan grafted carboxy functionalized polylactide nanoparticles for multidr...
 

Ähnlich wie are nanostructured lipid carrier are better then solid lipid nanoparticles

Nanoparticle Research Proposal 16-17 Linked In
Nanoparticle Research Proposal 16-17 Linked InNanoparticle Research Proposal 16-17 Linked In
Nanoparticle Research Proposal 16-17 Linked InNicole Hoffmann
 
Liposome Nanoparticles Lab Report
Liposome Nanoparticles Lab ReportLiposome Nanoparticles Lab Report
Liposome Nanoparticles Lab ReportAdam Rice
 
NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEMNIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEMKATHIR B.PHARM
 
NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEM NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEM MEENAAR2
 
NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEMNIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEMMEENAAR2
 
nanotechnology.pptx
nanotechnology.pptxnanotechnology.pptx
nanotechnology.pptxRiyaMathur18
 
Nanosponges:Targeted drug delivery system
Nanosponges:Targeted drug delivery system Nanosponges:Targeted drug delivery system
Nanosponges:Targeted drug delivery system rasika walunj
 
Nannoparticles Case Study
Nannoparticles Case StudyNannoparticles Case Study
Nannoparticles Case StudyBrianna Johnson
 
Design and Development of Effervescent Floating Tablet Dapagliflozin
Design and Development of Effervescent Floating Tablet DapagliflozinDesign and Development of Effervescent Floating Tablet Dapagliflozin
Design and Development of Effervescent Floating Tablet Dapagliflozinijtsrd
 
Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...
Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...
Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...debasishsahoo36
 
FORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptx
FORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptxFORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptx
FORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptxshivalisingla5
 
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...iosrphr_editor
 
Chitosan nanoparticles Dexibuprofen.pdf
Chitosan nanoparticles Dexibuprofen.pdfChitosan nanoparticles Dexibuprofen.pdf
Chitosan nanoparticles Dexibuprofen.pdfGOPALASATHEESKUMAR K
 
Niosomes presentation
Niosomes presentationNiosomes presentation
Niosomes presentationKhan Ramiz
 
Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...
Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...
Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...pharmaindexing
 
3.E) C Term Of The Van Deemter Equation Is Affected By The...
3.E) C Term Of The Van Deemter Equation Is Affected By The...3.E) C Term Of The Van Deemter Equation Is Affected By The...
3.E) C Term Of The Van Deemter Equation Is Affected By The...Jen Cloud
 
Bailey 2009 Langmuir
Bailey 2009 LangmuirBailey 2009 Langmuir
Bailey 2009 LangmuirMark Bailey
 
Nanotechnology as a dds by pradipkumar rathod
Nanotechnology as a dds by pradipkumar rathodNanotechnology as a dds by pradipkumar rathod
Nanotechnology as a dds by pradipkumar rathodPradipkumarRathod1
 

Ähnlich wie are nanostructured lipid carrier are better then solid lipid nanoparticles (20)

Nanoparticle Research Proposal 16-17 Linked In
Nanoparticle Research Proposal 16-17 Linked InNanoparticle Research Proposal 16-17 Linked In
Nanoparticle Research Proposal 16-17 Linked In
 
Liposome Nanoparticles Lab Report
Liposome Nanoparticles Lab ReportLiposome Nanoparticles Lab Report
Liposome Nanoparticles Lab Report
 
NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEMNIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEM
 
NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEM NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEM
 
NIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEMNIOSOMAL DRUG DELIVERY SYSTEM
NIOSOMAL DRUG DELIVERY SYSTEM
 
nanotechnology.pptx
nanotechnology.pptxnanotechnology.pptx
nanotechnology.pptx
 
Nanosponges:Targeted drug delivery system
Nanosponges:Targeted drug delivery system Nanosponges:Targeted drug delivery system
Nanosponges:Targeted drug delivery system
 
Nannoparticles Case Study
Nannoparticles Case StudyNannoparticles Case Study
Nannoparticles Case Study
 
Evaluation of Nanostructured lipid carriers (NLC)
Evaluation of Nanostructured lipid carriers (NLC)Evaluation of Nanostructured lipid carriers (NLC)
Evaluation of Nanostructured lipid carriers (NLC)
 
Design and Development of Effervescent Floating Tablet Dapagliflozin
Design and Development of Effervescent Floating Tablet DapagliflozinDesign and Development of Effervescent Floating Tablet Dapagliflozin
Design and Development of Effervescent Floating Tablet Dapagliflozin
 
SLN -.pptx
SLN -.pptxSLN -.pptx
SLN -.pptx
 
Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...
Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...
Surface PEGylation of hollow mesoporous silica nanoparticles via aminated int...
 
FORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptx
FORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptxFORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptx
FORMULATION AND EVALUATION OF ATORVASTATIN CALCIUM NIOSOMES.pptx
 
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org, call for paper, research...
 
Chitosan nanoparticles Dexibuprofen.pdf
Chitosan nanoparticles Dexibuprofen.pdfChitosan nanoparticles Dexibuprofen.pdf
Chitosan nanoparticles Dexibuprofen.pdf
 
Niosomes presentation
Niosomes presentationNiosomes presentation
Niosomes presentation
 
Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...
Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...
Formulation and Evaluation of Moxifloxacin Loaded Alginate Chitosan Nanoparti...
 
3.E) C Term Of The Van Deemter Equation Is Affected By The...
3.E) C Term Of The Van Deemter Equation Is Affected By The...3.E) C Term Of The Van Deemter Equation Is Affected By The...
3.E) C Term Of The Van Deemter Equation Is Affected By The...
 
Bailey 2009 Langmuir
Bailey 2009 LangmuirBailey 2009 Langmuir
Bailey 2009 Langmuir
 
Nanotechnology as a dds by pradipkumar rathod
Nanotechnology as a dds by pradipkumar rathodNanotechnology as a dds by pradipkumar rathod
Nanotechnology as a dds by pradipkumar rathod
 

Kürzlich hochgeladen

Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 

Kürzlich hochgeladen (20)

Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
Prelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quizPrelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quiz
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 

are nanostructured lipid carrier are better then solid lipid nanoparticles

  • 1. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles(SLNs): Development, characterizations and comparative evaluations of clotrimazole- loaded SLNs and NLCs? Presented by Devendra singh
  • 3. Introduction  From the recent past, biocompatible lipids have been attracting the attention of the formulation scientists as carriers for the delivery of poorly soluble drugs (Pouton, 2006).  Among biocompatible lipids, lipid nanoparticle formulations with solid matrix have gained huge popularity.  Generally, there are two types of lipid nanoparticles with solid matrix, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) (Das and Chaudhury, 2011).  Theses nanoparticles can be widely applied to deliver drugs/actives through oral, parenteral and topical routes (Almeida and Souto, 2007; Das and Souto, 2007.  However, the current focus of the SLNs and NLCs research is more inclined towards topical (especially dermal) application both in pharmaceutical and cosmetic purposes (Pardeike et al., 2009).
  • 4. SLNs are beneficial in many aspects such as:  possess negligible toxicity.  lipophilic compounds can be easily encapsulated.  bioavailability of highly lipophilic molecules can be increased via lymphatic uptake.  degradation of chemical/moisture/light/oxidation sensitive molecules can be prevented by their incorporation in the nanoparticle matrix.  sustained drug release from the nanoparticle matrix is possible due to solid nature of the matrix leading to prolonged drug release.  penetration through skin or mucus barrier is possible due to nano size.
  • 5. drawbacks of SLNs  polymorphic transitions of the lipid may occur with time due to the crystalline structure of solid lipid (Müller et al., 2002).  Lipid crystallizes in high-energetic lipid modifications, α and β immediately after preparation of SLNs.  In general, drug molecules stay in between the fatty acid chains or as amorphous clusters in crystal imperfections within SLN matrix. But, when lipid transform to low- energetic form, it form a perfect crystalline lattice that allows very small space for the drug molecules. Therefore, expulsion of encapsulated drug molecules may be observed during storage which leads to limited drug-loading capacity of SLNs.
  • 7. NLCs as alternate drug carrier systems over SLNs  In the process of further improvement and reduction of these drawbacks of SLNs, NLCs have been evolved as alternative drug carrier systems.  NLC matrix is composed of mixture of spatially different lipid molecules, normally mixture of solid and liquid lipid, which makes more imperfection in the matrix to accommodate more drug molecules than SLN.  It is expected that the drug-loading capacity will be enhanced, drug expulsion during storage will be minimized due to the imperfect crystal lattice and drug release profile can be easily modulated by varying the lipid matrix composition (Müller et al., 2002a; Radtke et al., 2005).
  • 8. Formulation technique: Emulsification ultra sonication technique: Melted lipid or lipid mixture o/w Nano emulsion Immediately placed in double walled plastic box filled with ice to cool it down The liquid nano-droplet transformed into solid nanoparticles dispersions Coarse o/w emulsion drug hot aqueous surfactant solution homogenize at 14000- 15000rpm Sonication at 75 c In case of SLNs solid lipid was weighed and heated 75 c In case of NLCs solid and liquid lipid heated 75 c
  • 9. Characterization Particle size, polydispersity index and zeta potential measurement:  For particle size and polydispersity index measurements, the diluted nanoparticle dispersion was poured into the disposable sizing cuvette which was then placed in the cuvette holder of the instrument and analyzed using the zetasizer software (DTS v 6.12, Malvern Instruments, UK).  For zeta potential measurement, disposable folded capillary cuvette was used. Air bubbles, if any, were removed from the capillary before measurement. All measurements were performed in triplicate.
  • 10. Drug loading and encapsulation efficiency measurement: Drug loading and encapsulation efficiency were determined by measuring the amount of encapsulated drug within the nanoparticles (Das et al., 2011). Unencapsulated insoluble drug (if any) were first filtered out through 3lm nitrocellulose membrane filter. Then, methanol (9.5 mL) was added in the filtered formulation(0.5 mL) and mixed well with the help of a cyclomixer. then centrifuged for 15 min at 5000 rpm and supernatant was collected. The drug concentration in the supernatant was measured by HPLC Drug encapsulation efficiency (EE) and drug loading (L) were calculated using the following equations: EE(%)= actual amount of drug in the filtered formulation-soluble unencapsulated drug x100 amount of drug added during formulation L(%) = actual amount of encapsulated drug x100 amount of lipid used to prepare the formulation
  • 11. Scanning electron microscopy study  Some researchers have used SEM for the morphology of SLNs (Varshosaz et al., 2010), the nanoparticles may not maintain their integrity and solid state during SEM analysis due to the increase in energy during measurment. Therefore, cryogenic field emission scanning electron microscopy was used to examine shape, size and surface morphology of the SLNs/NLCs.  few drops of the nanoparticle dispersion were placed on a copper stub and frozen in nitrogen slush at -196 C. The frozen sample was then stored in liquid nitrogen and transferred into the cryo preparation chamber attachedto a FESEM where the frozen sample was freeze-fractured, sublimed for 30 s at -95 C and sputtercoated with platinum for 120 s. Then the coated sample was placed onto the specimen stage of the FESEM at140 C and analyzed at an excitation voltage of 5 kV.
  • 12. Differential scanning calorimetry analysis  Firstly SNLs and NLCs samples are lyophilized, filled and blank NLCs and SLNs were subjected to DSC.  samples(4–5 mg) were kept in the standard aluminum pans and sealed. Then the pans were placed under isothermal condition at 25 C for 10 min. DSC analysis was performed at 10 C/min from 25 to 290C under a inert environment. An empty sealed pan was used as reference. The thermograms of the samples were recorded
  • 13. Drug release study The dialysis bag method was followed for the drug release study The day before the drug release experiment, dialysis tube (10 kDa molecular cut off) was treated closely following the protocol (Sigma) and soaked in the release media overnight. Phosphate buffer at pH 7.4 containing 2% Tween 80 was used as drug release media. Accurately measured 1 mL formulation was placed in the dialysis tube and both end of the tube was tightly tied to prevent any leakage. The tube containing formulation was then kept in an amber colored glass bottle containing 10 mL release media. The bottle was kept on a horizontal rotary shaker rotating at 100 rpm. Samples (5 mL release media) were withdrawn from the bottle at the predetermined time intervals and replaced by 5 mL fresh release media. The samples were then analyzed by HPLC to determine the amount of drug released from the formulation at different time points.
  • 15. Particle size  Particle size measurement was required to confirm the production of the particles in nano- range.  particle size was significantly influenced by most of the formulation and process variables.  Among the different lipid tested, SLNs prepared using Compritol 888ATO were smallest and SLNs prepared using Dynasan 118 were biggest.  However, no relationship between chemical structure of the lipids and particle size was observed. This might be because of the complex structure of these lipids.
  • 17. Effect of surfactant on particle size  Among the 4 non-ionic surfactant tested, SLNs prepared using Chremophore EL demonstrated lowest size, whereas SLNs prepared using PluronicF68 demonstrated largest size (fig.b)  Hydrophilic-lipophilic balance (HLB) value of 12–16 is considered to be ideal for the production of stable o/w emulsion.  In contrast, HLB value of Pluronic F68 is very high (>24). This might be the main reason of bigger particle size when PluronicF68 was used.
  • 19. Effect of sonication time on particle size. Particle size dramatically decreased with increasing sonication time However, the size reduction was not huge above 10 min sonication time. (Fig. 1C)
  • 20. Particle size dramatically decreased with increasing surfactant concentration (Fig. 1D).
  • 21. Polydispersity index  Polydispersity index (PI) indicates the width of the particle size distribution, which ranges from 0 to 1.  Theoretically, monodisperse populations indicates PI = 0. However, PI < 0.2 is considered as narrow size distribution.  Among the lipids, Compritol 888ATO produced SLNs with lowest PI and Geleol™ produced SLNs with highest PI (Fig. 1A).  Among the surfactants Chremophore EL produced SLNs with lowest PI and Pluronic F68 produced SLNs with highest PI (Fig. 1B).  PI decreased with increasing sonication time (up to 15 min) and surfactant concentration. PI was very high at 1–5 min sonication time and 0.5–1% surfactant concentration.
  • 22. Zeta potential  ZP refers to the surface charge of the particles. ZP ( ) indicates the degree of repulsion between close and similarly charged particles in the dispersion.  This repulsion force prevents aggregation of the particles. Therefore, ZP is a useful parameter to predict the physical stability of the SLN/NLC dispersions (Das and Chaudhury, 2011; Freitas and Müller, 1998).  The results indicate that ZP values were less than -20 mV for all prepared SLNs and NLCs, except SLNs prepared at 1% lipid concentration.  ZP of the SLNs prepared with different lipids decreased as follows: Precirol ATO5 > Compritol 888ATO > Suppocire NC > Geleol™ > Dynasan 114 > Imwitor 900 K > Dynasan118 (Fig. 1A)  There was no specific correlation between ZP and solid to liquid lipid ratio in NLCs (Fig. 2A).
  • 23. Drug encapsulation efficiency  Drug encapsulation efficiency (EE) was highest and lowest when SLNs were prepared with Compritol 888ATO (>87%) and Dynasan 118 (<76%) as lipid, respectively (Fig. 1A).  SLNs prepared with Chromophore EL as surfactant showed highest EE (>87%) (Fig. 1B). However, EE was > 79% when SLNs prepared with other surfactants too.  The results showed that EE of SLNs was not dependant on sonication time (Fig. 1C).  EE of SLNs significantly increased with increasing surfactant concentration.  However, insignificant increase in EE was noticed above 2% surfactant concentration. (Fig. 1D).
  • 24. Scanning electron microscopy  The images indicate that both SLNs and NLCs were spherical with size between 50 and 150 nm. Although it was not common, some particle agglomerates were observed (Fig. 3C).  The particle aggregations might be due to sticky nature of the lipid.  Surface morphology of both SLNs and NLCs were smooth and there is no visible difference between them (Fig. 3B–D).  The crystalline structures of clotrimazole were absent in the SEM images of SLNs and NLCs, which suggests absence of unencapsulated undissolved drug crystals in the dispersions.
  • 25. Fig. 3. SEM images of clotrimazole (A), solid lipid nanoparticles (B and C) and nanostructured lipid carriers (D)
  • 26. Drug release  Cumulative drug release from the nanoparticle dispersions were plotted against time (Fig.6).  SLNs and NLCs prepared at 4% drug to lipid ratio showed sustained and prolonged drug release. However, drug release rate of NLCs 4% was significantly faster than SLN-4% . (Fig. 6A)  Both SLNs and NLCs prepared at 8% drug to lipid ratio (i.e., SLN-8% and NLC- 8%) showed significantly slower drug release rate than their counterparts with 4% drug to lipid ratio.  There was no significant difference in drug release profile or rate between SLN-8% and NLC-8% .  There was also no significant difference in drug release profile of NLCs after 3 months storage in compare to fresh NLCs, while significant change drug release rate was observed in case of SLNs.
  • 27. Drug release plots. Comparison of drug release from SLNs and NLCs at 4% (SLN-4% and NLC-4%) and 8% (SLN-8% and NLC-8%) drug to lipid ratio (A). Effect of release media volume (10 mL versus 20 mL) on drug release from SLN-8% (B). Effect of dilution of SLNs-4% on drug release (C). Comparison of drug release from fresh and 3 months old SLN-4% and NLC-4% stored at 2–8C (D). Data represent mean SD (n= 3).
  • 28. Drug release contd..  lower drug release at 8% drug to lipid ratio than 4% drug to lipid ratio might be due to absence of proper sink condition during drug release study as drug amount was doubled but volume of release media was same (10 mL).  Therefore, another drug release experiment was performed on SLNs prepared with 8% drug to lipid ratio using 20 mL release media. The result indicates slightly faster drug release when 20 mL release media was used than 10 mL release media. (Fig. 6B)  In another experiment, effect of dilution of formulation on drug release was investigated. The experiment was performed as formulation is diluted after oral ingestion (in gastric fluid) or intravenous injection (in blood), whereas almost no dilution occur during topical application on skin. In this experiment, SLN dispersion was diuted 5 times with ultrapure water and then release study was performed in 10 mL release media (Fig. 6C).
  • 29. Conclusion  The study suggests the importance of controlling the critical formulation and process parameters during formulation as they greatly influenced the final product, such as particle size, polydispersity index, zeta potential, drug encapsulation efficiency.  Chemical characterizations (DSC) demonstrated slight difference in crystal structure between SLNs and NLCs, although crystalline peak(s) of clotrimazole disappeared in both SLNs and NLCs.  Sustained drug release was observed from SLNs and NLCs. NLCs exhibit the same release pattern after 3 month as fresh, while significant change was observed in case of SLNs  In the comparative study, NLCs exhibited faster drug release than SLNs at the low drug-loading.  Both tested SLNs and NLCs were stable at 2–8 C even at high drug-loading and also stable at 25 c at low drug loading. therefore, NLCs have an edge over SLNs.  Although both SLN and NLCs can be used as effective carrier of lipophilic drugs depending on desired drug release profile, NLCs might be better option than SLNs. Nevertheless different stabilizing route need to be evaluated in near future.
  • 30. Reference  Das S, Ng Wai K, Tan R. “Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles(SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?” Euro. Jur. Of ph sci. june 1, 2012.